Drug name
Last update: Jul 2026AKG-100
Developer(s)
Drug information
Not provided
AKG-100
Not provided
Small molecule
Oxazolidinone - 50S/70S protein inhibitor
1. Pharmacology: A highly stabilized, pegylated liposomal IV therapeutic belonging to the oxazolidinone antibiotic class. It delivers toxic payloads directly into target macrophages where Mycobacterium tuberculosis resides. 2. Clinical Pharmacokinetics: The liposomal nanoparticle structure shields the drug from rapid degradation. It provides sustained drug release for atleast 14 days after single dosage with 3.7 log₁₀ reduction in bacterial burden. 3. Safety & Efficacy: Phase 1 single-ascending-dose trials evaluated doses up to 850 mg in 40 healthy volunteers and 15 pulmonary TB patients. It was well-tolerated with zero discontinuations. All adverse events were mild and self-limiting. Early bactericidal activity data confirms robust efficacy against drug-resistant TB strains.
AKG-100 is under clinical invesigation at pHase 1 ascending dose trial
AKG-100 is under clinical invesigation at pHase 1 ascending dose trial, not approved yet
Therapeutic area(s)
- TB
- Other(s) : "Gram-positive bacterial infections."
- Treatment
- Prevention
Administration route
Intravenous
Associated long-acting platforms
Inorganic nanoparticles
Use of drug
- Administered by a community health worker
- Administered by a nurse
- Administered by a specialty health worker
- Monthly
Not provided
Dosage
Strength: 85mg/10mL; Dose : up to 850 mg (under Phase 1 Multi ascending dose (MAD) investigation)
850 mg adult dose
Not provided
Not provided
Not provided
Associated technologies
Not provided
Comment & Information
Developer(s)
Akagera Medicines
Akagera Medicines is a clinical-stage biopharmaceutical company founded in 2018 that develops novel lipid-nanoparticle and liposomal formulations of therapeutics and vaccines to treat infectious diseases such as Lassa Fever, HIV, RSV, and Influenza.
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients
Not provided
Not provided
Not provided
Delivery device(s)
Not provided
Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
WO2021258013A1
Drug Formulation
Akagera Medicines Inc
Not provided
Not provided
Ceased
Publications
There are no publication
Additional documents
No documents were uploaded
Useful links
Collaborate for development
Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology
Share technical information for match-making assessment
Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit
Work with MPP to expand access in LMICs
In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing